Barclays PLC has acquired voting rights in Dechra Pharmaceuticals PLC. The acquisition took place on August 30, 2023, and Barclays notified Dechra Pharmaceuticals on September 1, 2023. Barclays Capital Securities Limited, a subsidiary of Barclays PLC, is the shareholder with the voting rights. The total positions of Barclays PLC in Dechra Pharmaceuticals amount to 5.03% of the voting rights, with 3.16% attached to shares and 1.87% through financial instruments.

Barclays PLC holds a total of 5,730,374 voting rights in Dechra Pharmaceuticals. This includes 3,595,819 direct voting rights, representing 3.16% of the total, and 2,134,555 voting rights through financial instruments, representing 1.87% of the total. The financial instruments include equity swaps and portfolio swaps.

Barclays PLC is the ultimate controlling entity, and Barclays Capital Securities Limited is the controlled undertaking through which the voting rights and financial instruments are effectively held. Barclays PLC holds 3.16% of the voting rights in Dechra Pharmaceuticals directly and 5.03% through financial instruments.

No information is provided regarding proxy voting or additional details about the acquisition. The completion date of the acquisition was September 1, 2023, and the place of completion is not specified.